OraVerse
It’s about time.
OraVerse (phentolamine mesylate) injection is the first product introduced to the dental community by Novalar and addresses a long-standing need – reversal of local soft-tissue anesthesia following routine dental procedures.
Surveys show that the residual effects of local anesthetics, which include mumbling, drooling, and not being able to eat or drink normally, bother the vast majority of patients. And with 275 million anesthetic cartridges used annually, two-thirds of which are used in nonsurgical procedures, the unmet need to reverse local anesthesia is sizable, adding up to over 180 million opportunities for OraVerse.1
Additionally, dentists throughout the United States are looking for products that can differentiate their practice and offer patients a more comfortable experience. OraVerse can address that need as well.
OraVerse is a novel, effective, and safe anesthesia reversal agent that gets patients back to normal sensation and function twice as fast2, and it is the first and only product on the market that can make this claim. This makes OraVerse widely accepted among patients and dental professionals alike. Learn more here.
1 The 2008 Dental Products Market Share Study. Strategic Dental Marketing, Inc.
2 Median time to recovery of normal function was reduced by 60 minutes (50%) in the mandible and by 45 minutes (43%) in the maxilla compared with control. Median time to recovery of normal tongue sensation was reduced by 65 minutes (52%) compared with control.
